We are live on ! Find out more
MGNX icon

MacroGenics

132 hedge funds and large institutions have $835M invested in MacroGenics in 2016 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 47 increasing their positions, 36 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,075% more call options, than puts

Call options by funds: $2.77M | Put options by funds: $236K

89% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 9

31% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 36

10% more capital invested

Capital invested by funds: $760M → $835M (+$75.2M)

6% more funds holding

Funds holding: 125132 (+7)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
132
Holders Change
+7
Holders Change %
+5.6%
% of All Funds
3.52%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
17
Increased
47
Reduced
36
Closed
9
Calls
$2.77M
Puts
$236K
Net Calls
+$2.54M
Net Calls Change
+$1.81M

MGNX Hedge Fund Activity: Q3 2016 in Review

132 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in MacroGenics (MGNX) for Q3 2016, worth a combined $835M — up 9.9% from $760M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new MGNX positions and 9 closed out — a net gain of 8 holders — while 47 added to existing stakes and 36 trimmed.

The largest buyer was BB Biotech, adding an estimated $27.8M. The largest seller was Point72 Asset Management, cutting an estimated $22.1M.

  • 132 institutional investors held MacroGenics (MGNX) as of Q3 2016, up from 125 in Q2 2016.
  • Funds reported $835M of MacroGenics stock for Q3 2016, up 9.9% quarter-over-quarter.
  • 17 funds opened new MacroGenics positions in Q3 2016 and 9 closed out, a net change of +8 holders.
  • The largest MacroGenics buyer in Q3 2016 was BB Biotech, an estimated $27.8M added.
  • The largest MacroGenics seller in Q3 2016 was Point72 Asset Management, an estimated $22.1M sold.

Based on aggregated 13F filings for Q3 2016.